Skip to main content
Premium Trial:

Request an Annual Quote

David Danley, Jay Johnston, Gerard Vaillant, Laurence Hirsch, Thomas Caskey

Premium

David Danley has joined the board of directors of therapeutic antibody firm Hematech, the Sioux Falls, SD-based company said last week. He is the director for homeland security and defense programs at CombiMatrix. Prior to that, he was project manager of the chemical biological medical systems and joint vaccine acquisition program for the Department of Defense.


Jay Johnston and Gerard Vaillant have joined the board of directors of Luminex, the Austin, Texas-based company said last week. Laurence Hirsch and Thomas Caskey will retire from the board before this summer.

Johnston is chairman of QuesTek Innovations. In the past, he was corporate vice president for diagnostic assays and systems at Abbott Laboratories. He holds an MBA in general management from Amos Tuck School of Business Administration and an BA degree in public administration from Dartmouth College.

Until he retired last year, Vaillant was company group chairman of Johnson & Johnson He holds a master’s degree and superior certificate in biochemistry and industrial chemistry from Paris University of Sciences and a degree in marketing from Ecole Superieure de Commerce de Paris.

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.